Dr. Relan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1920 Colorado Ave
Santa Monica, CA 90404Phone+1 310-319-4700Fax+1 310-301-8751
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Family Medicine, 1999 - 2002
David Geffen School of Medicine at UCLAClass of 1999
UCLAMPH, Health Services, 1997 - 1998
UC Berkeley BA, Economics, 1990 - 1994
Certifications & Licensure
CA State Medical License 2001 - 2026- American Board of Family Medicine Family Medicine
Clinical Trials
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Start of enrollment: 2005 Jul 01
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Start of enrollment: 2003 Jun 01
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Start of enrollment: 2004 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 61 citationsAngioedema attacks in patients with hereditary angioedema : Local manifestations of a systemic activation processZonne L. M. Hofman, Anurag Relan, Sacha Zeerleder, Christian Drouet, Bruce L. Zuraw
The Journal of Allergy and Clinical Immunology. 2016-08-01 - 29 citationsA randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.V Koneti Rao, Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schuetz
Blood. 2023-03-02 - 15 citationsRecombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in childrenAvner Reshef, Vesna Grivcheva-Panovska, Aharon Kessel, Shmuel Kivity, Maria Klimaszewska-Rembiasz
Pediatric Allergy and Immunology. 2019-08-01
Journal Articles
- A Review of Hereditary Angioedema and Recombinant Human C1-Inhibitor TreatmentBork K, Triggiani M, Caballero T, Relan A, European Gastroenterology and Hepatology Review
Press Mentions
Pharming Appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific OfficerJune 17th, 2021- Pharming Announces First Patient Enrolled in Phase III Clinical Trial of Leniolisib for the Treatment of APDS in JapanAugust 10th, 2023
Industry Relationships
- Medical Director, Pharming2007 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
